Mikkola and colleagues examined the association between use of hormone therapy (HT) and death from Alzheimer’s disease (AD) or vascular dementia (VaD) in a sample of 489,105 Finnish women who had documented use of systemic HT on a nationwide drug reimbursement register [1]. A nationwide Finnish death register indicated that 1057 of those women died of AD and 581 died of VaD. Findings revealed that, compared to population averages, women who used HT for at least 5 years had a 15–19% reduced risk of death from AD, and use of HT for any period of time was associated with a 37–39% reduced risk of death from VaD. No reduction in AD was observed among women who used HT for less than 5 years, nor did age at initiation (< 60 years versus > 60 years) influence risk of AD or VaD.
Author(s)
-
Pauline Maki
Associate Professor of Psychiatry and Psychology, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, USA
Citations
-
Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, et al. Lower death risk for vascular dementia than for Alzheimer’s disease with postmenopausal hormone therapy users. J Clin Endocrinol Metab 2017;102:870-7
http://www.ncbi.nlm.nih.gov/pubmed/27906568 -
Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651-62
http://www.ncbi.nlm.nih.gov/pubmed/12771112 -
Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95
http://www.ncbi.nlm.nih.gov/pubmed/9496988 -
LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. Jama 2001;285:1489-99
http://www.ncbi.nlm.nih.gov/pubmed/11255426 -
Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2005;1052:57-74
http://www.ncbi.nlm.nih.gov/pubmed/16024751 -
Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology 2017;88:1062-8
http://www.ncbi.nlm.nih.gov/pubmed/28202700 -
Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 1986;27:227-35
http://www.ncbi.nlm.nih.gov/pubmed/3734624 -
Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology 2009;73:1729-37
http://www.ncbi.nlm.nih.gov/pubmed/19933973 -
Solomon A, Ngandu T, Soininen H, Hallikainen MM, Kivipelto M, Laatikainen T. Validity of dementia and Alzheimer’s disease diagnoses in Finnish national registers. Alzheimers Dement 2014;10:303-9
http://www.ncbi.nlm.nih.gov/pubmed/23849592 -
Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol 2006;63:945-50
http://www.ncbi.nlm.nih.gov/pubmed/16831962
